BioCentury

7:00 AM GMT, Apr 5, 2010
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Product Development

No Regrets for Antisoma

The vagaries of drug development are such that even carefully thought out clinical programs can fail. Thus Antisoma plc says it has no regrets about the way it and partner Novartis AG have run development for ASA404, which failed last week in a Phase III trial in non-small cell lung cancer.

The partners halted the international Phase III ATTRACT-1 trial in 1,200 previously untreated NSCLC patients after an interim analysis showed there was "little or no prospect" that ASA404 plus carboplatin and Taxol paclitaxel would meet the primary endpoint of significantly improving overall survival (OS) vs. placebo plus chemotherapy.

"I think we felt we were following a pretty gold standard path for developing cancer drugs," said Daniel Elger, Antisoma's VP of marketing and communications.

ASA404 is a vascular disrupting agent

Read the full 1279 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.